Jump to content

Levdobutamine

From Wikipedia, the free encyclopedia
(Redirected from LY206243)

Levdobutamine
Clinical data
Other namesLevodobutamine; (S)-Dobutamine; LY-206243
Drug classSympathomimetic; β1-Adrenergic receptor agonist; Positive inotrope
Identifiers
  • 4-[2-[[(2S)-4-(4-hydroxyphenyl)butan-2-yl]amino]ethyl]benzene-1,2-diol
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H23NO3
Molar mass301.386 g·mol−1
3D model (JSmol)
  • C[C@@H](CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
  • InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3/t13-/m0/s1
  • Key:JRWZLRBJNMZMFE-ZDUSSCGKSA-N

Levdobutamine (INNTooltip International Nonproprietary Name; developmental code name LY-206243; also known as (S)-dobutamine) is a sympathomimetic, selective β1-adrenergic receptor agonist, and positive inotrope which was never marketed.[1][2] It is the (S)-enantiomer of dobutamine.[1]

References

[edit]
  1. ^ a b Morton IK, Hall JM (2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Netherlands. p. 164. ISBN 978-94-011-4439-1. Retrieved 27 February 2025.
  2. ^ Milne G, Zeman E (2017). Ashgate Handbook of Cardiovascular Agents: An International Guide to 1900 Drugs in Current Use: An International Guide to 1900 Drugs in Current Use. Routledge Revivals. Taylor & Francis. p. 228. ISBN 978-1-351-74240-5. Retrieved 27 February 2025.